Health Care • Biotechnology: Laboratory Analytical Instruments
$0.62 ▲ +0.00
(+0.49%)
MKT CAP: $244.7M • VOL: 445.8K
52W L $1 52W H $2
LAB // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $85.3M | $91.0M | $106.3M |
| YoY Revenue Growth % | -6.2% | -14.4% | — |
| Gross Profit | $42.5M | $44.9M | — |
| Gross Margin % | 49.9% | 49.3% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$110.2M | -$127.5M | -$76.6M |
| Operating Margin % | -80.0% | -80.0% | -72.0% |
| Net Income (GAAP) | -$74.9M | -$138.9M | -$74.7M |
| EBITDA (Normalized) | -$103.6M | -$120.8M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$74.3M | -$143.5M | -$43.3M |
| Capital Expenditures (CapEx) | $8.3M | $8.4M | — |
| Free Cash Flow (FCF) | -$82.6M | -$151.8M | -$43.3M |
| FCF Margin % | -80.0% | -80.0% | -40.7% |
| Return on Invested Capital (ROIC %) | -28.7% | -33.0% | — |
| Cash & Short-Term Equivalents | $120.9M | $166.7M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $424.3M | $471.7M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR LAB.